Objetivo
Dendritic cell (DC) immune-biology has enormous potential for development of new immunotherapies for cancer and infectious disease. Europe possesses a critical mass of leaders in the field who have pioneered many innovative advances and provided initial pr oof of principle for the approach. This NoE, DC-THERA, will integrate the activities of 25 participant groups of scientists and clinicians and 6 high quality SMEs across Europe. It will incorporate additional groups, particularly from future member states, as Associated Members of the Network Their collective expertise and resources will be forged into an ambitious Joint Programme of Activities to restructure the field. It will translate genomic, proteomic and bioinformatic information, with knowledge from molecular cell biology and pre-clinical models, into therapeutic endpoints: clinical trials of DC-based therapies for cancer and HIV. Towards this end, four thematic S&T Clusters have been defined, with a fifth for horizontal activities. The latter inc ludes development of synergistic links with other Networks, providing added value to EC Programmes by underpinning all projects developing new vaccine strategies for major killer diseases. The Network will implement an IT-based integrated knowledge managem ent system and provide a centralised European resource of databases for the field. DC-THERA will develop new research tools, integrate existing and new technological platforms, recruit additional support staff, and make these available as shared resources for all partners It will implement an ambitious Education and Training Programme, including new PhD studentships, a Visiting Scholars Scheme, high quality training courses, and a postgraduate degree in translational DC immunobiology. DC-THERA will contribu te to the European biotechnology sector and have a major impact on European policy-making for the future. DC-THERA will evolve itself into a Centre of Excellence for DC Biology,with a lasting and global impact.
Ámbito científico
- medical and health scienceshealth sciencesinfectious diseasesRNA virusesHIV
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicineimmunologyimmunotherapy
Palabras clave
Convocatoria de propuestas
FP6-2003-LIFESCIHEALTH-I
Consulte otros proyectos de esta convocatoria
Régimen de financiación
NoE - Network of ExcellenceCoordinador
OXFORD
Reino Unido
Ver en el mapa
Participantes (31)
NIJMEGEN
Ver en el mapa
LONDON
Ver en el mapa
MILAN
Ver en el mapa
OXFORD
Ver en el mapa
BRUSSELS
Ver en el mapa
SIENA
Ver en el mapa
MILAN
Ver en el mapa
DURHAM, NC
Ver en el mapa
MILANO
Ver en el mapa
PARIS
Ver en el mapa
BRUSSELS
Ver en el mapa
FIRENZE
Ver en el mapa
STOCKHOLM
Ver en el mapa
LEIDEN
Ver en el mapa
MARSEILLE
Ver en el mapa
MILAN
Ver en el mapa
BERLIN
Ver en el mapa
LONDON
Ver en el mapa
BELLINZONA
Ver en el mapa
ZURICH
Ver en el mapa
BRUSSELS
Ver en el mapa
MUENCHEN
Ver en el mapa
VILLEJUIF
Ver en el mapa
MILAN
Ver en el mapa
MARTINSRIED
Ver en el mapa
ROZZANO, MILAN
Ver en el mapa
ERLANGEN
Ver en el mapa
PARIS
Ver en el mapa
ROME
Ver en el mapa
BRUXELLES
Ver en el mapa
PARIS
Ver en el mapa